TECH — Bio-Techne Corporation

Bio-Techne Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $295.9 million, flat year-over-year on both an organic and reported basis.
• Adjusted EPS: $0.46, up 10% year-over-year; GAAP EPS increased to $0.24 from $0.22.
• Adjusted Operating Margin: 31.1%, up 100 basis points year-over-year.
• Adjusted Gross Margin: 68.5%, down from 70.5% the previous year, attributed to unfavorable product mix.
• Operating Cash Flow: $82.4 million, with $5.9 million in net capital expenditures.
• Bank Debt: $260 million, down $40 million sequentially.

2. Strategic Updates and Business Highlights

• Growth Verticals: The company focuses on four strategic growth areas: cell therapy, proteomic analytical instrumentation, spatial biology, and precision diagnostic tools, which now account for 47% of total revenue.
• Cell Therapy: Excluding two major customers with FDA Fast Track designations, cell therapy showed strong growth, with overall GMP reagent demand down over 30% due to these designations.
• Geographic Performance: China reported mid-single-digit growth for the third consecutive quarter, while APAC (excluding China) grew nearly 20%.
• Product Innovations: Introduced new assays for the Ella platform and launched the Culturex Synthetic Hydrogel for organoid applications, reflecting a commitment to innovation.

3. Forward Guidance and Outlook

• Q3 Expectations: Anticipated organic growth to be consistent with Q2, with underlying growth expected to be mid-single digits when excluding customer-specific headwinds.
• Fiscal Year 2026 Outlook: The company maintains a low single-digit growth outlook for the full year, with expectations for improvement as headwinds from cell therapy customers abate.
• Fiscal Year 2027: Positive sentiment around biotech funding and academic budgets suggests potential for stronger growth as the company laps easier comparisons.

4. Bad News, Challenges, or Points of Concern

• Flat Revenue Growth: Organic revenue growth was flat due to headwinds from timing impacts related to major customers in cell therapy.
• Declining Academic Market: The U.S. academic market showed a modest decline, although stabilization is expected with favorable federal funding developments.
• Gross Margin Pressure: The decline in gross margin was driven by an unfavorable product mix and lower-margin customer orders in diagnostics.
• Emerging Biotech Struggles: Revenue from emerging biotech customers declined mid-single digits, reflecting ongoing funding pressures.

5. Notable Q&A Insights

• Customer Sentiment: There is optimism regarding improving customer sentiment in biotech, with funding conditions stabilizing and showing signs of recovery.
• Cell Therapy Impact: The two major customers' Fast Track designations are expected to create a temporary headwind, with a gradual return to normalized growth anticipated in fiscal 2027.
• M&A Strategy: The company remains focused on M&A as a priority for capital allocation, with interest in expanding capabilities in novel antibodies and cell therapy.
• AI Integration: Management views AI as a potential tailwind, enabling customers to enhance their R&D productivity and specificity in material needs.

Overall, Bio-Techne's Q2 2026 results reflect a stable performance amidst challenging market conditions, with strategic investments and a focus on innovation positioning the company for future growth.